Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (RCKT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · RCKT · as of Jun 9, 2026
Activity summary
Buy transactions
2
P-Purchase only
Sell transactions
32
12 Months
Buy/Sell ratio
0.06
Buy/Sell (by trades)
Overall sentiment
Rocket Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
RCKT insider buying and selling by quarter
RCKT insider selling · RCKT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · RCKT ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
RCKT executive sell shares · RCKT board member insider trading · RCKT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 21, 2026 | Shah Gaurav CEO | Option | 76,490 | $129K | Form 4 |
| May 21, 2026 | Shah Gaurav CEO | Sale | 55,684 | $172K | Form 4 |
| May 19, 2026 | Shah Gaurav CEO | Sale | 2,409 | $7K | Form 4 |
| May 19, 2026 | Wilson Martin General Counsel | Sale | 662 | $2K | Form 4 |
| May 19, 2026 | Militello John See Remarks | Sale | 384 | $1K | Form 4 |
| May 13, 2026 | Wilson Martin General Counsel | Sale | 3,361 | $12K | Form 4 |
| May 13, 2026 | Shah Gaurav CEO | Sale | 2,728 | $10K | Form 4 |
| May 13, 2026 | Militello John See Remarks | Sale | 855 | $3K | Form 4 |
| May 7, 2026 | Chaudhuri Sarbani See Remarks | Sale | 17,650 | $68K | Form 4 |
| Feb 18, 2026 | Militello John See Remarks | Sale | 1,157 | $4K | Form 4 |
| Feb 18, 2026 | Shah Gaurav CEO | Sale | 5,990 | $20K | Form 4 |
| Feb 18, 2026 | Wilson Martin General Counsel | Sale | 1,376 | $5K | Form 4 |
| Feb 13, 2026 | Wilson Martin General Counsel | Sale | 12,253 | $41K | Form 4 |
| Feb 13, 2026 | Militello John See Remarks | Sale | 3,726 | $12K | Form 4 |
| Feb 13, 2026 | Shah Gaurav CEO | Sale | 12,279 | $41K | Form 4 |
| Feb 11, 2026 | Shah Gaurav CEO | Award | 286,028 | — | Form 4 |
| Feb 11, 2026 | Militello John See Remarks | Award | 29,982 | — | Form 4 |
| Feb 11, 2026 | Wilson Martin General Counsel | Award | 311,813 | — | Form 4 |
| Feb 11, 2026 | Rizvi Syed Ali-aamir Chief Medical Officer | Award | 61,963 | — | Form 4 |
| Feb 11, 2026 | Stevens Christopher James COO | Award | 61,963 | — | Form 4 |
| Feb 11, 2026 | Chaudhuri Sarbani See Remarks | Award | 125,924 | — | Form 4 |
| Jan 2, 2026 | Bjork Elisabeth Director | Purchase | 10,000 | $34K | Form 4 |
| Nov 18, 2025 | Schwartz Jonathan David See Remarks | Sale | 2,545 | $8K | Form 4 |
| Nov 18, 2025 | Shah Gaurav CEO · Director | Sale | 6,276 | $19K | Form 4 |
| Nov 18, 2025 | Militello John See Remarks | Sale | 1,086 | $3K | Form 4 |
Rizvi Syed Ali-aamir
Chief Medical Officer
Date
Feb 11
Shares
61,963
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About RCKT insider trading
RCKT insider trades
Rocket Pharmaceuticals, Inc. (RCKT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Militello John (See Remarks), Wilson Martin (General Counsel), Shah Gaurav (CEO). Over the past 12 months, 5 insiders have filed transactions with the SEC. RCKT insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Rocket Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
RCKT insider trading · 5 questionsThe insiders of Rocket Pharmaceuticals, Inc. (RCKT) include executives and directors such as Militello John (See Remarks), Wilson Martin (General Counsel), Shah Gaurav (CEO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026